Brind.

Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.

1 report, 1 independent Updated Oct 21

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Leerink partners Barclays MarketBeat

Keep exploring

The entities involved

Leerink partners
U.S. investment bank
- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Sun 19:40
- Intuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.Sat 07:31
Barclays
British bank
- A Barclays branch in Burnley was targeted, leading to a CPS case where a judge considered terrorist connections.Fri 18:44
- Malik participated in an attack against a Barclays branch located in Burnley.Fri 18:44
MarketBeat
American personal finance blog
- MarketBeat provided average stock ratings for Cloudastructure Inc, a company listed on the Nasdaq exchange.01:16
- MarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Sun 23:25

Related events

Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.Oct 10
MarketBeat aggregated consensus ratings and average price targets for Atour Lifestyle Holdings Limited. Morgan Stanley provided an overweight rating and price target.Jul 10
MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.Oct 15

Coverage

Newest first; wire copies grouped

Oct 21tickerreport.com